346 related articles for article (PubMed ID: 18226083)
21. Antibiotic options for treating community-acquired MRSA.
Powell JP; Wenzel RP
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):299-307. PubMed ID: 18588495
[TBL] [Abstract][Full Text] [Related]
22. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
Mariani PG; Sader HS; Jones RN
J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
[No Abstract] [Full Text] [Related]
23. Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient.
Weis F; Beiras-Fernandez A; Kaczmarek I; Sodian R; Vicol C; Reichart B; Weis M
Ann Thorac Surg; 2007 Jul; 84(1):269-70. PubMed ID: 17588430
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
Riser MS; Bland CM; Rudisill CN; Bookstaver PB
Ann Pharmacother; 2010 Nov; 44(11):1832-5. PubMed ID: 20959502
[TBL] [Abstract][Full Text] [Related]
25. Treatment challenges in the management of complicated skin and soft-tissue infections.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():17-25. PubMed ID: 18226086
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of daptomycin against Staphylococcus aureus isolates from skin and skin structure infections of trauma patients.
Behera B; Jain N; Sharma S; Mathur P; Misra MC
J Infect; 2010 Jul; 61(2):195-6. PubMed ID: 20547179
[No Abstract] [Full Text] [Related]
27. Methicillin-resistant Staphylococcus aureus: an evolving clinical challenge.
Karchmer AW; Bayer AS
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S342-3. PubMed ID: 18462088
[No Abstract] [Full Text] [Related]
28. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
Hair PI; Keam SJ
Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
[TBL] [Abstract][Full Text] [Related]
29. Drugs for MRSA skin and soft-tissue infections.
Med Lett Drugs Ther; 2014 May; 56(1442):39-40. PubMed ID: 24818839
[No Abstract] [Full Text] [Related]
30. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
Alder J
Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
[TBL] [Abstract][Full Text] [Related]
31. Daptomycin (Cubicin) for skin and soft tissue infections.
Med Lett Drugs Ther; 2004 Feb; 46(1175):11-2. PubMed ID: 14749611
[No Abstract] [Full Text] [Related]
32. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice.
Dryden M; Andrasevic AT; Bassetti M; Bouza E; Chastre J; Cornaglia G; Esposito S; French G; Giamarellou H; Gyssens IC; Nathwani D; Unal S; Voss A
Clin Microbiol Infect; 2010 Mar; 16 Suppl 1():3-30. PubMed ID: 20222890
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin.
Lee DH; Palermo B; Chowdhury M
Clin Infect Dis; 2008 Aug; 47(4):588-90. PubMed ID: 18636964
[No Abstract] [Full Text] [Related]
34. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.
Sader HS; Watters AA; Fritsche TR; Jones RN
J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740
[TBL] [Abstract][Full Text] [Related]
35. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, meticillin-resistant Staphylococcus aureus in a patient with chronic kidney disease.
Kuo CC; Wu VC; Huang YT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2009 Jan; 33(1):96-8. PubMed ID: 18790610
[No Abstract] [Full Text] [Related]
36. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
37. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections.
Fergie J; Purcell K
Pediatr Infect Dis J; 2008 Jan; 27(1):67-8. PubMed ID: 18162942
[No Abstract] [Full Text] [Related]
38. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.
Gould IM; Miró JM; Rybak MJ
Int J Antimicrob Agents; 2013 Sep; 42(3):202-10. PubMed ID: 23845504
[TBL] [Abstract][Full Text] [Related]
39. Future directions with daptomycin.
Livermore DM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii41-iii49. PubMed ID: 18829725
[TBL] [Abstract][Full Text] [Related]
40. [The second life of daptomycin: analysis of a successful come-back].
Decousser JW; Doucet Populaire F
Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
